[go: up one dir, main page]

EA200300567A1 - TREATMENT OF THE ALARM CONDITIONS - Google Patents

TREATMENT OF THE ALARM CONDITIONS

Info

Publication number
EA200300567A1
EA200300567A1 EA200300567A EA200300567A EA200300567A1 EA 200300567 A1 EA200300567 A1 EA 200300567A1 EA 200300567 A EA200300567 A EA 200300567A EA 200300567 A EA200300567 A EA 200300567A EA 200300567 A1 EA200300567 A1 EA 200300567A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
alarm conditions
published
search report
international search
Prior art date
Application number
EA200300567A
Other languages
Russian (ru)
Inventor
Холли Рид Томассон
Дэвид Михелсон
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA200300567A1 publication Critical patent/EA200300567A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Селективные ингибиторы вторичного захвата норэпинефрина применяют для лечения состояний тревоги, в особенности обсессивно-компульсивного состояния.Отчет о международном поиске был опубликован 2003.12.24.Selective norepinephrine secondary seizure inhibitors are used to treat anxiety states, especially obsessive-compulsive state. The international search report was published 2003.12.24.

EA200300567A 2000-11-15 2001-11-06 TREATMENT OF THE ALARM CONDITIONS EA200300567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24901000P 2000-11-15 2000-11-15
US26536201P 2001-01-31 2001-01-31
PCT/US2001/027801 WO2002040006A2 (en) 2000-11-15 2001-11-06 Treatment of anxiety disorders

Publications (1)

Publication Number Publication Date
EA200300567A1 true EA200300567A1 (en) 2004-10-28

Family

ID=26939750

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300567A EA200300567A1 (en) 2000-11-15 2001-11-06 TREATMENT OF THE ALARM CONDITIONS

Country Status (16)

Country Link
EP (1) EP1395253A2 (en)
JP (1) JP2004529073A (en)
KR (1) KR20030051812A (en)
CN (1) CN1822825A (en)
AU (1) AU2002217757A1 (en)
BR (1) BR0115301A (en)
CA (1) CA2426069A1 (en)
CZ (1) CZ20031339A3 (en)
EA (1) EA200300567A1 (en)
HR (1) HRP20030384A2 (en)
IL (1) IL155874A0 (en)
MX (1) MXPA03004190A (en)
NO (1) NO20032156D0 (en)
PL (1) PL366119A1 (en)
SK (1) SK5422003A3 (en)
WO (1) WO2002040006A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030092012A (en) * 2001-03-06 2003-12-03 일라이 릴리 앤드 캄파니 Inhibitor of Monoamine Uptake
CN1674907A (en) * 2002-08-14 2005-09-28 法玛西亚普强责任有限公司 Use of reboxetine for the treatment of hot flashes
GB0309440D0 (en) * 2003-04-25 2003-06-04 Lilly Co Eli Quinolone derivatives
WO2004103356A2 (en) * 2003-05-15 2004-12-02 Eli Lilly And Company Treatment of emotional dysregulation
US20070015786A1 (en) * 2003-12-12 2007-01-18 Eli Lily And Company Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
EP2234960A2 (en) 2008-01-09 2010-10-06 Mayo Foundation for Medical Education and Research Inhibiting neurotransmitter reuptake
WO2011056788A2 (en) * 2009-11-03 2011-05-12 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
US20120220665A1 (en) * 2009-11-03 2012-08-30 Mayo Foundation For Medical Education And Research Inhibiting Neurotransmitter Reuptake
US9944618B2 (en) 2013-03-14 2018-04-17 Mayo Foundation For Medical Education And Research Inhibiting neurotransmitter reuptake
AU2020214641B2 (en) * 2019-02-01 2025-09-25 Hoffman Technologies Llc Compositions and methods for treating anxiety-related disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2931997A (en) * 1996-05-07 1997-11-26 Merck & Co., Inc. Treatment of mood disorders with a growth hormone secretagogue
IT1305322B1 (en) * 1998-04-23 2001-05-04 Pharmacia & Upjohn Spa Use of reboxetine for treating obsessive compulsive disorder and panic disorder
EP2090312A1 (en) * 1999-07-01 2009-08-19 Pharmacia & Upjohn Company LLC (S,S) reboxetine for treating attention deficit disorder

Also Published As

Publication number Publication date
EP1395253A2 (en) 2004-03-10
JP2004529073A (en) 2004-09-24
CZ20031339A3 (en) 2003-10-15
MXPA03004190A (en) 2003-09-22
CA2426069A1 (en) 2002-05-23
PL366119A1 (en) 2005-01-24
SK5422003A3 (en) 2003-12-02
WO2002040006A2 (en) 2002-05-23
HRP20030384A2 (en) 2003-08-31
KR20030051812A (en) 2003-06-25
NO20032156L (en) 2003-05-13
NO20032156D0 (en) 2003-05-13
CN1822825A (en) 2006-08-23
BR0115301A (en) 2004-12-14
AU2002217757A1 (en) 2002-05-27
IL155874A0 (en) 2003-12-23
WO2002040006A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
YU5503A (en) Non-steroidal inflammation inhibitors
ATE288431T1 (en) SUBSTITUTED BIZYCLIC DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
EA200000351A1 (en) TREATMENT OF CONDUCTIVE VIOLATIONS
EA200300906A1 (en) NEW SPYROTRICYCLIC DERIVATIVES AND THEIR APPLICATION AS PHOSPHODESTERASE-7 INHIBITORS
DE60218493D1 (en) SUBSTITUTED 7-AZA-Ä2.2.1ÜBICYCLOHEPTANE FOR THE TREATMENT OF DISEASES
EA200101232A1 (en) PHENOXYPROPYLAMINE COMPOUNDS
CO4970820A1 (en) BISULPHATE SALT OF HIV-PROTEASE INHIBITOR
IS6655A (en) Cyclopentanoindole, preparations containing such compounds and treatment methods
DK1420801T3 (en) Use of fucans for the treatment of adhesions, arthritis and psoreasis
NO20005237D0 (en) Heterocyclic substituted amides used as calpain inhibitors
EA200300836A1 (en) DERIVATIVES OF PHTHALASINON-PIPERIDINE AS PDE4 INHIBITORS
EA200300567A1 (en) TREATMENT OF THE ALARM CONDITIONS
DE60231107D1 (en) TETRAHYDRO-PYRAZINOÄ1,2-AÜINDOLE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
PE20030061A1 (en) 1-BIARIL-1,8-NAPHTHYRIDIN-4-ONA AS PHOSPHODIESTERASE-4 INHIBITORS
MXPA02009313A (en) Heterocyclic acylsulfimides, a method for their production, agents containing the same and their use as pesticides.
DE60132494D1 (en) COPPER CHELVER FOR THE TREATMENT OF EYE IGNITIONS
DE60033809D1 (en) INHIBITORS OF METAL PROTEINASES
DK1204659T3 (en) Serotonergic benzofurans
DK1438034T3 (en) Use of -phenyl-3-dimethylaminiopropane compounds in the treatment of urinary incontinence
EA200200798A1 (en) CALCYLYTIC COMPOUNDS
DK1161239T3 (en) 3-Cyclopropylmethoxy-4-difluoromethoxy-N- (3,5-dichloropyrid-4-yl) benzamide for the treatment of disseminated sclerosis
ATE403422T1 (en) SUBSTITUTED HYDRAZONE AS AN INHIBITOR OF CYCLOOXYGENASE-2
ATE345135T1 (en) TROPANE DERIVATIVES HAVING DOPAMINE RUPUP INHIBITOR ACTION FOR THE TREATMENT OF ISCHEMIC DISEASES
EA200400661A1 (en) Phenylalkins
DE60220825D1 (en) USE OF NOREPINEPHRINE RECEPTACLES FOR THE TREATMENT OF TICKS